Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
Conclusions The effectiveness and safety results of eribulin as the first- or second-line treatment were favorable. Thus, these suggest eribulin may be a first-line treatment candidate for patients with HER2-negative advanced breast cancer in Japan.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Diabetes | Drugs & Pharmacology | Endocrinology | HER2 | Investigational New Drugs | Japan Health | Neurology | Peripheral Neuropathy | Study